Skip to content

Ascentage Pharma

US · AAPG #3045 by market cap Listed 2025
11.97 -0.47 -3.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 16.39 Cheap vs history 33rd percentile
5-year average 32.46 · #480 of 513 in Biotechnology
P/E ratio -6.21 Expensive vs history 98th percentile
5-year average -22.24 · forward -7.42
P/S ratio 14.17 Cheap vs history 14th percentile
5-year average 29.63 · forward 13.01 · #197 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Ascentage Pharma (AAPG) 1.12B -5.07 13.39 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value22.10 Economic moatNone UncertaintyVery High

Trading 84.7% below Morningstar's fair value estimate.

Fair value

Given the significant price pressure over the last year, Ascentage Pharma Group International might appear cheap. However, to account for the possibility that it may be a value trap, we've restricted its rating to 3 stars. The stock currently trades at a 34% discount to our quantitative fair value estimate of $22.10 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 5.0, which lies in the bottom 45% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 6.6%, for example, ranks in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Ascentage Pharma discussion 0 comments

Add a comment